— Registry → CAPLUS

file registry

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 11:46:27 ON 16 JAN 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 14 JAN 2004 HIGHEST RN 637725-36-1
DICTIONARY FILE UPDATES: 14 JAN 2004 HIGHEST RN 637725-36-1

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2003

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=> **s {ra]r[ia]rpk[la]/sqep**
GAPS, WILDCARDS, AND BRACKETS ARE INVALID FOR "EXACT" SEQUENCE FIELD CODES.

=> **s [ra]r[ia]rpk[la]/sqsp and sql=7**
42 [RA]R[IA]RPK[LA]/SQSP
44750 SQL=7
L1 42 [RA]R[IA]RPK[LA]/SQSP AND SQL=7

=> **file caplus**

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	32.19	32.40

FILE 'CAPLUS' ENTERED AT 11:48:08 ON 16 JAN 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 16 Jan 2004 VOL 140 ISS 4
FILE LAST UPDATED: 15 Jan 2004 (20040115/ED)

This file contains CAS Registry Numbers for easy and accurate

substance identification.

=> **s l1**
L2 10 L1

=> **d bib,kwic 1-10**

L2 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN
Full Text | More Like This | References

AN 2000:288742 CAPLUS
DN 133:53837
TI Analogs of dynorphin A (6-12) with N-methyl amino acids: biological activity and structure of side-products
AU Burov, Sergey; Vlasov, Guennadii; Dorosh, Marina; Schkarubsaya, Soya; Schkurov, Valery; Muradymov, Marat; Wei, Edward T.
CS Institute of Macromolecular Compounds, Academy of Sciences, St.-Petersburg, 199004, Russia
SO Peptides 1998, Proceedings of the European Peptide Symposium, 25th, Budapest, Aug. 30-Sept. 4, 1998 (1999), Meeting Date 1998, 810-811. Editor(s): Bajusz, Sandor; Hudecz, Ferenc. Publisher: Akademiai Kiado, Budapest, Hung.
CODEN: 68WKAY
DT Conference
LA English
RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT
IT **83690-60-2D**, Dynorphin A 6-12, analogs **209521-51-7**
277751-04-9 **277751-05-0** **277751-06-1**
277751-07-2 **277751-08-3** **277751-09-4**
277751-10-7
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(anti-inflammatory action of dynorphin A (6-12) analogs with N-Me amino acids)

L2 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN
Full Text | More Like This | References

AN 2000:288726 CAPLUS
DN 133:145029
TI Design of optimal analogs of 6-12 fragment of dynorphin A with high anti-inflammatory activity using D, L - peptide library approach
AU Vlasov, Guennady P.; Wei, Edward T.; Burov, Sergey V.; Korol'kov, Valeriy I.
CS Institute of Macromolecular Compounds, Russian Academy of Sciences, Petersburg, Russia
SO Peptides 1998, Proceedings of the European Peptide Symposium, 25th, Budapest, Aug. 30-Sept. 4, 1998 (1999), Meeting Date 1998, 778-779. Editor(s): Bajusz, Sandor; Hudecz, Ferenc. Publisher: Akademiai Kiado, Budapest, Hung.
CODEN: 68WKAY
DT Conference
LA English
RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT
IT **83690-60-2D**, Dynorphin A 6-12, analogs **286965-41-1**
286965-42-2 **286965-43-3** **286965-44-4**
286965-45-5 **286965-46-6** **286965-47-7**
287121-42-0 **287121-43-1** **287121-44-2**
287121-45-3 **287182-47-2**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(design of optimal analogs of the 6-12 fragment of dynorphin A with high anti-inflammatory activity using a D,L-peptide library approach)

L2 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN

Full Text | Citing References

AN 1999:566078 CAPLUS
DN 131:194806
TI Melanocortin receptor antagonists and modulations of melanocortin receptor activity
IN Wei, Edward T.; Quillan, J. Mark; Sadee, Wolfgang; Vlasov, Guennady P.; Chang, J. K.
PA The Regents of the University of California, USA
SO PCT Int. Appl., 41 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9943709	A2	19990902	WO 1999-US4111	19990225
	WO 9943709	A3	20000113		
	W: AU, CA, JP				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	US 6228840	B1	20010508	US 1998-31902	19980227
	AU 9933111	A1	19990915	AU 1999-33111	19990225
	US 2002004485	A1	20020110	US 2001-849592	20010504
PRAI	US 1998-31902	A	19980227		
	WO 1999-US4111	W	19990225		

OS MARPAT 131:194806
IT 79515-34-7 84211-35-8, Dynorphin A(2-13) 200959-47-3
209521-51-7 **209521-64-2** **215527-99-4**
215528-00-0 **215528-01-1** 215528-02-2 215528-03-3
215528-04-4 **240810-91-7** **240810-92-8**
240810-93-9 **240810-94-0** **240810-95-1**
240810-96-2 240810-97-3 240810-98-4 240810-99-5 240811-00-1
240811-01-2 240811-02-3 240811-03-4 240811-04-5 240811-05-6
240811-06-7 240811-07-8
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(melanocortin receptor antagonists and modulations of melanocortin receptor activity in relation to melanoma treatment)

L2 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN

Full Text | Citing References

AN 1998:597967 CAPLUS
DN 129:339948
TI Modified dynorphin A (6-12) analogs that suppress thermal edema
AU Vlasov, Guennady P.; Burov, Sergey V.; Korolkov, Vladimir; Glynskaya, Olga V.; Thomas, Holly A.; Wei, Edward
CS State Institute of Highly Pure Biopreparations, St. Petersburg, 197110, Russia
SO Peptides 1996, Proceedings of the European Peptide Symposium, 24th, Edinburgh, Sept. 8-13, 1996 (1998), Meeting Date 1996, 877-878.
Editor(s): Ramage, Robert; Epton, Roger. Publisher: Mayflower Scientific, Kingswinford, UK.

CODEN: 66RCA5
DT Conference
LA English
RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT
IT 83608-80-4, Dynorphin A(2-17) **83690-60-2D**, Dynorphin A 6-12, analogs **161875-00-9** **163132-93-2** **209521-51-7** **209521-52-8** **209521-53-9** **209521-64-2** **215527-99-4** 215528-00-0 **215528-01-1** 215528-02-2 215528-03-3 215528-04-4
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(modified dynorphin A (6-12) analogs that suppress thermal edema)

L2 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN
Full Text More References
AN 1998:350384 CAPLUS
DN 129:90564
TI Dynorphin A(6-12) analogs suppress thermal edema
AU Wei, Edward T.; Thomas, Holly A.; Gjerde, Eli-Anne; Reed, Rolf K.; Burov, Sergey V.; Korolkov, Valerij I.; Glynskaya, Oxana V.; Dorosh, Marina Y.; Vlasov, Guennady P.
CS School of Public Health, University of California, Berkeley, CA, 94720, USA
SO Peptides (New York) (1998), 19(4), 767-775
CODEN: PPTDD5; ISSN: 0196-9781
PB Elsevier Science Inc.
DT Journal
LA English
RE.CNT 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT
IT 83608-80-4, Dynorphin A(2-17) 88161-22-2D, Dynorphin A, analogs **161875-00-9**, N-Acetyl-[D-Leu12]-dynorphin A(6-12)-NH2 **163132-93-2**, N-Acetyl-dynorphin A(6-12)-NH2 **209521-51-7** **209521-52-8** **209521-53-9** **209521-54-0** **209521-55-1** **209521-56-2** **209521-57-3** **209521-58-4** 209521-59-5 **209521-60-8** 209521-61-9 209521-62-0 209521-63-1 **209521-64-2**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(dynorphin A(6-12) analogs suppress thermal edema)

L2 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN
Full Text More References
AN 1995:746010 CAPLUS
DN 123:133370
TI Metabolism of dynorphin A 1-13 in human blood and plasma
AU Mueller, Stefan; Hochhaus, Guenther
CS Dep. Pharm., Univ. Florida, Gainesville, FL, 32610, USA
SO Pharmaceutical Research (1995), 12(8), 1165-70
CODEN: PHREEB; ISSN: 0724-8741
PB Plenum
DT Journal
LA English
IT 79985-35-6, Dynorphin A 1-12 79994-24-4, Dynorphin A 1-10 **83690-60-2**, Dynorphin A 6-12 84211-35-8, Dynorphin A 2-13 89202-80-2, Dynorphin A 3-13 116920-16-2, Dynorphin A 3-8 145143-20-0, Dynorphin A 2-8 153538-61-5, Dynorphin A2-12 153538-64-8, Dynorphin A 2-10 153538-77-3, Dynorphin A 3-12 163132-92-1, Dynorphin A 4-12 166984-16-3, Dynorphin A 4-8 166984-17-4, Dynorphin A 5-12

166984-18-5, Dynorphin A 7-12
RL: BSU (Biological study, unclassified); MFM (Metabolic formation); BIOL (Biological study); FORM (Formation, nonpreparative)
(dynorphin A 1-13 metab. in human blood and plasma)

L2 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN
Full Text | Citing References
AN 1995:541838 CAPLUS
DN 122:282447
TI Potent inhibition of thermal edema in rat by des-Tyr-dynorphin A
AU Thomas, Holly A.; Wei, Edward T.
CS Sch. Public Health, Univ. California, Berkeley, CA, 94720, USA
SO Peptides (Tarrytown, New York) (1995), 16(3), 547-50
CODEN: PPTDD5; ISSN: 0196-9781
PB Elsevier
DT Journal
LA English
IT 72957-38-1, Dynorphin A(1-13) 83608-80-4, Dynorphin A(2-17) **83690-60-2** 87079-95-6, Dynorphin A(6-17) 88161-22-2, Dynorphin A 89202-80-2, Dynorphin A(3-13) 96249-44-4 150398-27-9, Dynorphin A(2-14) 153538-61-5 153538-69-3 153538-77-3 **161875-00-9** 163132-90-9 163132-91-0 163132-92-1, 4-12-Dynorphin A (pig) **163132-93-2**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(dynorphin A and dynorphin A analogs inhibition of thermal edema in relation to structure)

L2 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN
Full Text | Citing References
AN 1995:446711 CAPLUS
DN 122:205184
TI Anti-inflammatory composition and method with des-tyr dynorphin and analogues
IN Wei, Edward T.; Thomas, Holly A.
PA Reagents of the University of California, USA
SO PCT Int. Appl., 24 pp
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9429337	A1	19941222	WO 1994-US6502	19940609
	W: AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KG, KP, KR, KZ, LK, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, UZ, VN				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 5482930	A	19960109	US 1993-74210	19930609
	AU 9470583	A1	19950103	AU 1994-70583	19940609
	AU 679241	B2	19970626		
	JP 08511541	T2	19961203	JP 1994-502096	19940609
	EP 751954	A1	19970108	EP 1994-919428	19940609
	EP 751954	B1	20011205		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, NL, PT, SE				
	AT 210149	E	20011215	AT 1994-919428	19940609
PRAI	US 1993-74210	A	19930609		
	WO 1994-US6502	W	19940609		

IT **83690-60-2** 88161-22-2, Dynorphin A

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(core of anti-inflammatory des-tyr dynorphin)

IT 83608-80-4 161874-98-2 161874-99-3 **161875-00-9**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(des-tyr dynorphin; anti-inflammatory compn. contg. des-tyr dynorphin and analogs)

L2 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN
Full Text | More References

AN 1986:553511 CAPLUS
DN 105:153511
TI Polymer-supported biopolymer synthesis: 5. Ultra-high load solid (gel) phase peptide synthesis - the stepwise elaboration of quasi-homogeneous peptide gel networks?
AU Epton, R.; Marr, G.; McGinn, B. J.; Small, P. W.; Wellings, D. A.; Williams, A.
CS Sch. Appl. Sci., Wolverhampton Polytech., Wolverhampton, WV1 1LY, UK
SO International Journal of Biological Macromolecules (1985), 7(5), 289-98
CODEN: IJBMDR; ISSN: 0141-8130
DT Journal
LA English
IT **83690-49-7DP**, ester with [(hydroxyphenyl)ethyl]acrylamide crosslinked polymer 104411-81-6DP, ester with [(hydroxyphenyl)ethyl]acrylamide crosslinked polymer 104411-82-7DP, ester with [(hydroxyphenyl)ethyl]acrylamide crosslinked polymer
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and resin cleavage of, by hydrazinolysis)
IT **83690-55-5P** 104411-83-8P 104411-84-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, by ultra-high load solid-phase method)

L2 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN
Full Text | More References

AN 1982:616701 CAPLUS
DN 97:216701
TI Polymer-supported biopolymer synthesis. 2. Phenolic poly(acryloylmorpholine)-based preparation of protected arginyl acylpeptide segments and derived arginyl peptides
AU Buckle, M.; Epton, R.; Marr, G.; Small, P. W.; Hudson, D.
CS Dep. Phys. Sci., Wolverhampton Polytech., Wolverhampton, WV1 1LY, UK
SO International Journal of Biological Macromolecules (1982), 4(5), 275-80
CODEN: IJBMDR; ISSN: 0141-8130
DT Journal
LA English
IT 4530-20-5DP, poly(acryoylmorpholine)-based phenolic resin-bound 83690-45-3P **83690-49-7DP**, poly(acryoylmorpholine)-based phenolic resin-bound
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and deprotection of)
IT 83690-56-6P **83690-57-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and hydrolysis of)
IT 83690-45-3DP, poly(acryoylmorpholine)-based phenolic resin-bound **83690-49-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and resin cleavage of)
IT 81657-13-8P **83690-55-5P** 83690-59-9P **83690-61-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)

(prepn. of)

=> **s anisoyl?**
L3 2763 ANISOYL?

=> **s l3 and dynorphin?**
3566 DYNORPHIN?
L4 3 L3 AND DYNORPHIN?

=> **d bib,kwic 1-3**

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN
Full Text | More Formats | References

AN 2000:288726 CAPLUS
DN 133:145029
TI Design of optimal analogs of 6-12 fragment of **dynorphin** A with high anti-inflammatory activity using D, L - peptide library approach
AU Vlasov, Guennady P.; Wei, Edward T.; Burov, Sergey V.; Korol'kov, Valeriy I.
CS Institute of Macromolecular Compounds, Russian Academy of Sciences, Petersburg, Russia
SO Peptides 1998, Proceedings of the European Peptide Symposium, 25th, Budapest, Aug. 30-Sept. 4, 1998 (1999), Meeting Date 1998, 778-779. Editor(s): Bajusz, Sandor; Hudecz, Ferenc. Publisher: Akademiai Kiado, Budapest, Hung.
CODEN: 68WKAY
DT Conference
LA English
RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT
TI Design of optimal analogs of 6-12 fragment of **dynorphin** A with high anti-inflammatory activity using D, L - peptide library approach
AB Previously the authors found that des-Tyr'-**dynorphin** A, **Dynorphin** (2-17) acts as an agonist to inhibit the acute phase of the inflammatory response. The replacement of Dyn A (2-5) with the **anisoyl** group (Ani), removal of Dyn A (13-17) and changing L-Leu to D-Leu produced the peptide analog of **Dynorphin** A (m-Ani-Arg6-Arg-Ile-Arg-Pro-Lys-D-Leu12-NH2), m-Ani-[D-Leu12] Dyn A (6-12), whose anti-inflammatory activity was equiv. to **dynorphin** A (2-17). Amino acid positions responsible for the anti-inflammatory activity of Dyn A (6-12) were detd. Taking into account that biol. active conformation of a peptide is predetd. by stereochem. of all its amino acid residues, the authors used a combinatorial D,L-peptide chem. approach for the optimal design of **Dynorphin** A (6-12) peptides using the m-Ani-[D-Leu12] Dyn A (6-12)-NH2 as a prototype. Using this approach, the Dyn A (6-12) analog m-**Anisoyl**-D-Arg-L-Arg-L-Ile-D-Arg-L-Pro-D-Lys-D-Leu-NH2 with a high level of anti-inflammatory activity was detected.
ST design **dynorphin** A analog antiinflammatory agent
IT Anti-inflammatory agents
Drug design
(design of optimal analogs of the 6-12 fragment of **dynorphin** A with high anti-inflammatory activity using a D,L-peptide library approach)
IT Structure-activity relationship
(inflammation-inhibiting; design of optimal analogs of the 6-12 fragment of **dynorphin** A with high anti-inflammatory activity using a D,L-peptide library approach)
IT 83690-60-2D, **Dynorphin** A 6-12, analogs 286965-41-1
286965-42-2 286965-43-3 286965-44-4 286965-45-5 286965-46-6
286965-47-7 287121-42-0 287121-43-1 287121-44-2 287121-45-3
287182-47-2

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(design of optimal analogs of the 6-12 fragment of **dynorphin** A with high anti-inflammatory activity using a D,L-peptide library approach)

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN

Full Text | More References

AN 1999:566078 CAPLUS
DN 131:194806
TI Melanocortin receptor antagonists and modulations of melanocortin receptor activity
IN Wei, Edward T.; Quillan, J. Mark; Sadee, Wolfgang; Vlasov, Guennady P.; Chang, J. K.
PA The Regents of the University of California, USA
SO PCT Int. Appl., 41 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9943709	A2	19990902	WO 1999-US4111	19990225
	WO 9943709	A3	20000113		
	W: AU, CA, JP				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	US 6228840	B1	20010508	US 1998-31902	19980227
	AU 9933111	A1	19990915	AU 1999-33111	19990225
	US 2002004485	A1	20020110	US 2001-849592	20010504
PRAI	US 1998-31902	A	19980227		
	WO 1999-US4111	W	19990225		

OS MARPAT 131:194806
AB The clin. outcome of disseminated melanoma is grim. Small mol. wt. antagonists (preferably about seven amino acid residues) specific for melanocortin receptor (MCR) on melanoma cells are provided for the therapy of melanoma as well as in other conditions where modulation of MCR is of clin. significance. A particularly preferred antagonist is p-**anisoyl**-[D-Arg6,9, D-Lys11, D-Leu12] **dynorphin** A(6-12)-NH2, which is an excellent antagonist of the MCR-1 receptor.
IT 79515-34-7 84211-35-8, **Dynorphin** A(2-13) 200959-47-3
209521-51-7 209521-64-2 215527-99-4 215528-00-0 215528-01-1
215528-02-2 215528-03-3 215528-04-4 240810-91-7 240810-92-8
240810-93-9 240810-94-0 240810-95-1 240810-96-2 240810-97-3
240810-98-4 240810-99-5 240811-00-1 240811-01-2 240811-02-3
240811-03-4 240811-04-5 240811-05-6 240811-06-7 240811-07-8
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(melanocortin receptor antagonists and modulations of melanocortin receptor activity in relation to melanoma treatment)

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN

Full Text | More References

AN 1998:350384 CAPLUS
DN 129:90564
TI **Dynorphin** A(6-12) analogs suppress thermal edema
AU Wei, Edward T.; Thomas, Holly A.; Gjerde, Eli-Anne; Reed, Rolf K.; Burov, Sergey V.; Korolkov, Valerij I.; Glynskaya, Oxana V.; Dorosh, Marina Y.;

Vlasov, Guennady P.
CS School of Public Health, University of California, Berkeley, CA, 94720, USA
SO Peptides (New York) (1998), 19(4), 767-775
CODEN: PPTDD5; ISSN: 0196-9781
PB Elsevier Science Inc.
DT Journal
LA English
RE.CNT 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

TI **Dynorphin** A(6-12) analogs suppress thermal edema

AB **Dynorphin** A (Dyn A) is a 17-residue opioid peptide derived from prodynorphin precursors found in mammalian tissues. Removal of Tyr1 from Dyn A produces a peptide that is more potent than Dyn A in attenuating the acute phase of the inflammatory response, as measured by inhibition of heat-induced edema in the anesthetized rat's paw (exposure to 58° water for 1 min). Dyn A(2-17), however, no longer interacts with opioid receptors. It was postulated that the non-opioid anti-inflammatory actions of Dyn A(2-17) may reside in Dyn A(6-12); i.e., Arg-Arg-Ile-Arg-Pro-Lys-Leu, here we report on the activities of Dyn A(6-12) analogs modified by substitutions on the N terminus, by single N-Me substitution and by single replacement of residues by alanine. The results indicated that the minimal sequence required for an anti-edema ED50 of <1.0 μmol/kg i.v. was **anisoyl**-Arg6-Arg7-Xaa8-Arg9-Pro10-Xaa11-Xaa12-NH2. A prototype, p-**anisoyl**-[D-Leu12] Dyn A(6-12)-NH2, with an ED50 of 0.20 μmol/kg i.v. compared to an ED50 of 0.08 μmol/kg i.v. for Dyn A(2-17), was selected for further tests of biol. activity. This analog, like Dyn A(2-17), lowered blood pressure in anesthetized rats. In a model of neurogenic inflammation, produced by antidromic stimulation of the vagus in the anesthetized rat, p-**anisoyl**-[D-Leu12] Dyn A(6-12)-NH2, 0.23 μmol/kg i.v., attenuated the negativity of tracheal tissue interstitial pressure, which normally develops after nerve stimulation. Modulation of interstitial pressure may be the mechanistic basis for the anti-edema properties of these Dyn A(6-12) analogs.

ST **dynorphin** A analog antiinflammatory structure activity; thermal edema **dynorphin** A analog

IT Anti-inflammatory agents
Blood pressure
Edema
(**dynorphin** A(6-12) analogs suppress thermal edema)

IT Temperature effects, biological
(heat; **dynorphin** A(6-12) analogs suppress thermal edema)

IT Structure-activity relationship
(inflammation-inhibiting; **dynorphin** A(6-12) analogs suppress thermal edema)

IT 83608-80-4, **Dynorphin** A(2-17) 88161-22-2D, **Dynorphin** A, analogs 161875-00-9, N-Acetyl-[D-Leu12]-**dynorphin** A(6-12)-NH2 163132-93-2, N-Acetyl-**dynorphin** A(6-12)-NH2 209521-51-7 209521-52-8 209521-53-9 209521-54-0 209521-55-1 209521-56-2 209521-57-3 209521-58-4 209521-59-5 209521-60-8 209521-61-9 209521-62-0 209521-63-1 209521-64-2
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(**dynorphin** A(6-12) analogs suppress thermal edema)